Pfizer Inc. $PFE Shares Sold by HighPoint Advisor Group LLC

HighPoint Advisor Group LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 28.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 169,565 shares of the biopharmaceutical company’s stock after selling 67,040 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Pfizer were worth $4,321,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Linscomb Wealth Inc. increased its stake in shares of Pfizer by 2.5% during the third quarter. Linscomb Wealth Inc. now owns 254,263 shares of the biopharmaceutical company’s stock worth $6,479,000 after acquiring an additional 6,196 shares during the period. Bessemer Group Inc. lifted its position in Pfizer by 5.6% in the third quarter. Bessemer Group Inc. now owns 129,761 shares of the biopharmaceutical company’s stock valued at $3,306,000 after purchasing an additional 6,896 shares during the period. SBI Securities Co. Ltd. boosted its holdings in Pfizer by 21.4% in the 3rd quarter. SBI Securities Co. Ltd. now owns 509,451 shares of the biopharmaceutical company’s stock valued at $12,981,000 after purchasing an additional 89,822 shares in the last quarter. Howe & Rusling Inc. increased its position in Pfizer by 3.3% during the 3rd quarter. Howe & Rusling Inc. now owns 30,580 shares of the biopharmaceutical company’s stock worth $779,000 after purchasing an additional 981 shares during the period. Finally, Savant Capital LLC raised its stake in shares of Pfizer by 3.8% during the 3rd quarter. Savant Capital LLC now owns 286,158 shares of the biopharmaceutical company’s stock worth $7,291,000 after buying an additional 10,434 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 4.1%

PFE opened at $26.83 on Thursday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The business has a 50-day moving average of $25.57 and a two-hundred day moving average of $25.07. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The stock has a market capitalization of $152.55 billion, a price-to-earnings ratio of 19.73 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the business earned $0.63 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. UBS Group initiated coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.